Key Record Dates
| ClinicalTrials.gov Identifier: | NCT02659384 |
|---|---|
| Brief Title: | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer |
| First Submitted : | January 14, 2016 |
| First Submitted that Met QC Criteria : | January 15, 2016 |
| First Posted : | January 20, 2016 (Estimate) |
| Last Update Submitted that Met QC Criteria : | July 30, 2020 |
| Last Update Posted : | July 31, 2020 |